Literature DB >> 16102589

Ovarian cancer is a heterogeneous disease.

Vivian Wang1, Cheng Li, Ming Lin, William Welch, Deborah Bell, Yuk-Fu Wong, Ross Berkowitz, Samuel C Mok, Christina A Bandera.   

Abstract

The purpose of this study was to systematically evaluate the molecular profiles of different histologic types of epithelial ovarian cancer before the disease has metastasized beyond the ovary. Stage 1 epithelial ovarian cancers were chosen for analysis of early genetic events associated with different cell types. Allelotyping of 47 cases was performed using 224 polymorphic markers. Analysis with Fisher's exact test found markers specific for grade 3 tumors and clear cell histology. Hierarchal clustering analysis using dChip software revealed that the pattern of allele loss in eight regions on four chromosomes led to grouping of grade 3 tumors, endometrioid (grades 1 and 2) tumors, and clear cell tumors. We conclude that ovarian cancer is a heterogeneous disease in which histologic phenotypes correlate with distinct genetic patterns.

Entities:  

Mesh:

Year:  2005        PMID: 16102589     DOI: 10.1016/j.cancergencyto.2004.12.014

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

Review 1.  Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma.

Authors:  Yiying Wang; Maggie Mang; Yue Wang; Lijie Wang; Robert Klein; Beihua Kong; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 2.  Ovarian cancer epidemiology in the era of collaborative team science.

Authors:  Rikki A Cannioto; Britton Trabert; Elizabeth M Poole; Joellen M Schildkraut
Journal:  Cancer Causes Control       Date:  2017-03-10       Impact factor: 2.506

Review 3.  Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.

Authors:  Mingo M H Yung; Hextan Y S Ngan; David W Chan
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-01-12       Impact factor: 3.848

Review 4.  Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer.

Authors:  Sarah P Blagden
Journal:  Front Oncol       Date:  2015-06-30       Impact factor: 6.244

5.  Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.

Authors:  Ae Lee Jeong; Sora Han; Sunyi Lee; Jeong Su Park; Yiling Lu; Shuangxing Yu; Jane Li; Kyung-Hee Chun; Gordon B Mills; Young Yang
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

6.  Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.

Authors:  Haibo Pan; Fang Wang; Gary O Rankin; Yon Rojanasakul; Youying Tu; Yi Charlie Chen
Journal:  Int J Oncol       Date:  2017-10-03       Impact factor: 5.650

7.  An integrative model for recurrence in ovarian cancer.

Authors:  Alexandros Laios; Sharon A O'Toole; Richard Flavin; Cara Martin; Martina Ring; Noreen Gleeson; Tom D'Arcy; Eamonn P J McGuinness; Orla Sheils; Brian L Sheppard; John J O' Leary
Journal:  Mol Cancer       Date:  2008-01-22       Impact factor: 27.401

8.  Linking the ovarian cancer transcriptome and immunome.

Authors:  Ronald Rapberger; Paul Perco; Cornelia Sax; Thomas Pangerl; Christian Siehs; Dietmar Pils; Andreas Bernthaler; Arno Lukas; Bernd Mayer; Michael Krainer
Journal:  BMC Syst Biol       Date:  2008-01-03

Review 9.  Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.

Authors:  Tae Hun Kim; Dong Hoon Suh; Mi-Kyung Kim; Yong Sang Song
Journal:  Biomed Res Int       Date:  2014-06-24       Impact factor: 3.411

10.  MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer.

Authors:  Han-Li Huang; Min-Wu Chao; Ya-Chi Li; Li-Hsun Chang; Chun-Han Chen; Mei-Chuan Chen; Chun-Chun Cheng; Jing-Ping Liou; Che-Ming Teng; Shiow-Lin Pan
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.